Compare BPRN & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BPRN | MDWD |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.5M | 212.1M |
| IPO Year | 2022 | 2013 |
| Metric | BPRN | MDWD |
|---|---|---|
| Price | $34.84 | $16.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 4.8K | ★ 50.8K |
| Earning Date | 04-23-2026 | 05-20-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | ★ 74.84 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.96 | $48.92 |
| Revenue Next Year | $6.13 | $35.04 |
| P/E Ratio | $38.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.21 | $14.90 |
| 52 Week High | $37.99 | $22.51 |
| Indicator | BPRN | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 47.43 |
| Support Level | $34.66 | $16.26 |
| Resistance Level | $36.53 | $18.38 |
| Average True Range (ATR) | 0.70 | 0.49 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 61.93 | 35.99 |
Princeton Bancorp Inc is a full-service financial institution providing personal and business banking services, including checking and savings accounts, as well as a range of lending products such as residential, commercial, construction, and consumer loans, including home equity loans and lines of credit. The Bank operates branches and conducts loan origination activities in areas of the New York City metropolitan area. Its loan portfolio is segmented into commercial real estate (including owner-occupied, non-owner-occupied, and multi-family properties), construction loans (mainly for residential developments), commercial and industrial loans (for business purposes), residential real estate loans (secured by one-to-four family properties), and consumer/HELOC loans.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.